Literature DB >> 16914604

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

Jakob Ryskjaer1, Carolyn F Deacon, Richard D Carr, Thure Krarup, Sten Madsbad, Jens Holst, Tina Vilsbøll.   

Abstract

OBJECTIVE: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide are incretin hormones, secreted in response to meal ingestion. The incretin hormones stimulate insulin secretion and are essential for the maintenance of normal plasma glucose concentrations. Both incretin hormones are metabolized quickly by the enzyme dipeptidyl peptidase-IV (DPP-IV). It is well known that type-2 diabetic patients have an impaired incretin effect. Therefore, the aim of the present study was to investigate plasma DPP-IV activity in the fasting and the postprandial state in type-2 diabetic patients and control subjects.
DESIGN: The study included two protocols. Protocol one involved 40 fasting type-2 diabetic patients (28 men); age 61 +/- 1.4 (mean +/- s.e.m.) years; body mass index (BMI) 31 +/- 0.6 kg/m(2); HbAlc 7.2 +/- 0.2%; and 20 matched control subjects (14 men) were studied. Protocol two involved eight type-2 diabetic patients (six men); age 63 +/- 1.2 years; BMI 33 +/- 0.5 kg/m(2); HbAlc 7.5 +/- 0.4%; eight matched control subjects were included.
METHODS: In protocol one, fasting values of DPP-IV activity were evaluated and in protocol two, postprandial DPP-IV activity during a standard meal test (566 kcal) was estimated.
RESULTS: Mean fasting plasma DPP-IV activity (expressed as degradation of GLP-1) was significantly higher in this patient group compared with the control subjects (67.5 +/- 1.9 vs 56.8 +/- 2.2 fmol GLP-1/h (mean +/- s.e.m.); P=0.001). In the type-2 diabetic patients, DPP-IV activity was positively correlated to FPG and HbAlc and negatively to the duration of diabetes and age of the patients. No postprandial changes were seen in plasma DPP-IV activity in any of the groups.
CONCLUSIONS: Plasma DPP-IVactivity increases in the fasting state and is positively correlated to FPG and HbAlc levels, but plasma DPP-IV activity is not altered following meal ingestion and acute changes in plasma glucose.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914604     DOI: 10.1530/eje.1.02221

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  62 in total

Review 1.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 2.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

3.  Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Authors:  L D Carbone; P Bůžková; H A Fink; J A Robbins; M Bethel; C M Isales; W D Hill
Journal:  Osteoporos Int       Date:  2017-02-02       Impact factor: 4.507

Review 4.  The incretin system and cardiometabolic disease.

Authors:  Paul E Szmitko; Lawrence A Leiter; Subodh Verma
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

Review 5.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

6.  Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients.

Authors:  E Mannucci; L Pala; M Monami; L Da Vico; G Bardini; I Dicembrini; S Ciani; C Lamanna; N Marchionni; C M Rotella
Journal:  J Endocrinol Invest       Date:  2009-09-11       Impact factor: 4.256

Review 7.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

8.  Dipeptidyl peptidase IV and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Vivian C Luft; Maria Inês Schmidt; James S Pankow; Ron C Hoogeveen; David Couper; Gerardo Heiss; Bruce B Duncan
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 19.112

9.  Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.

Authors:  Gábor Firneisz; Tímea Varga; Gabriella Lengyel; János Fehér; Dóra Ghyczy; Barna Wichmann; László Selmeci; Zsolt Tulassay; Károly Rácz; Anikó Somogyi
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

Review 10.  Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

Authors:  Kristina Blaslov; Tomislav Bulum; Karin Zibar; Lea Duvnjak
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.